novo nordisk semaglutide products and competitors Wegovy Ozempic maker forecasts sharp drop in revenue for 2026 | Pharmaceuticals industry Health Canada Approves New Novo

Clinical trials show GLP-1 agonists produce significantly greater weight losstypically 1522% of body weight over 68 weekscompared to phentermine's effects

In response, your intestines send a signal to your brain that triggers a rise in the GLP-1 hormone

PlexusDx operates in all 50 states without requiring insurance, making it easier to add a specialized weight loss team to your existing IBD management plan

The main task of Ozempic is to increase insulin release, slow down stomach emptying, and reduce sugar production by the liver

If you find yourself stuck with no weight loss after several weeks despite consistent calorie tracking, the issue may be metabolic adaptation from previously eating too little

March 2026: A Science Day has been scheduled in the federal GLP-1 litigation involving NAION claims